ANDA 217841, held by Abon Pharmaceuticals. Venlafaxine Hydrochloride.
As of Nov 18, 2026, ANDA 217841 (Venlafaxine Hydrochloride), held by Abon Pharmaceuticals, was first approved by FDA on Feb 7, 2025, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 7, 2025 | Original application | Approved | None posted |
| Venlafaxine HydrochlorideEQ 150MG BASE · tablet, extended release;oral | Venlafaxine Hydrochloride | Rx |
| Venlafaxine HydrochlorideEQ 225MG BASE · tablet, extended release;oral | Venlafaxine Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters